SPOP and prostate cancer: Recurrent gene fusions in the oncogenic transcription factor ERG, present in 40% to 50% of prostate cancers, define one such subclass, while a second distinct class, comprising 10% of prostate cancers, is defined by recurrent mutations in SPOP (1, 2).